Dynavax Technologies (NASDAQ:DVAX) Upgraded at ValuEngine

Dynavax Technologies (NASDAQ:DVAX) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday, April 1st, ValuEngine reports.

Other equities analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Thursday, March 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 price target (down previously from $32.00) on shares of Dynavax Technologies in a research note on Tuesday, February 26th. Finally, BidaskClub downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $27.00.

NASDAQ DVAX traded down $0.03 during trading hours on Monday, hitting $6.48. 5,791 shares of the stock were exchanged, compared to its average volume of 1,085,831. The stock has a market capitalization of $416.62 million, a P/E ratio of -2.51 and a beta of 0.67. Dynavax Technologies has a 12-month low of $6.22 and a 12-month high of $20.10. The company has a quick ratio of 4.08, a current ratio of 4.58 and a debt-to-equity ratio of 1.60.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.04). The firm had revenue of $3.90 million for the quarter, compared to analysts’ expectations of $3.43 million. Dynavax Technologies had a negative return on equity of 139.00% and a negative net margin of 1,938.27%. The company’s revenue for the quarter was up 18471.4% on a year-over-year basis. During the same period in the prior year, the company earned ($0.45) earnings per share. On average, equities research analysts expect that Dynavax Technologies will post -2.35 earnings per share for the current fiscal year.

In related news, SVP Robert Coffman sold 63,202 shares of the firm’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $9.03, for a total transaction of $570,714.06. Following the completion of the sale, the senior vice president now directly owns 86,268 shares of the company’s stock, valued at approximately $779,000.04. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP David Louis Johnson sold 20,765 shares of the firm’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $9.03, for a total transaction of $187,507.95. Following the sale, the vice president now directly owns 52,786 shares of the company’s stock, valued at $476,657.58. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 119,411 shares of company stock valued at $1,075,091. Company insiders own 3.47% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Advisor Group Inc. grew its holdings in Dynavax Technologies by 515.3% during the 4th quarter. Advisor Group Inc. now owns 4,473 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 3,746 shares in the last quarter. Quantbot Technologies LP acquired a new position in Dynavax Technologies during the 3rd quarter worth $131,000. Pacer Advisors Inc. acquired a new position in shares of Dynavax Technologies in the 3rd quarter valued at about $132,000. Legal & General Group Plc boosted its holdings in shares of Dynavax Technologies by 18.7% in the 4th quarter. Legal & General Group Plc now owns 11,814 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 1,860 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Dynavax Technologies in the 4th quarter valued at about $117,000. 84.11% of the stock is owned by institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Featured Article: NASDAQ

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.